Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Background/Aims With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the USA. Therefore, we aimed to compare the long-term outcomes of patients with MASLD and cirrhosis with and without bariatric surgery.
Methods Patients were retrospectively identified from the California Department of Healthcare Access and Information database, 2005 to 2019, for a population-based cohort study. Propensity score matching (PSM) was used to balance background risks between patients with cirrhosis who underwent bariatric surgery and those who did not. Overall, liver-related and non-liver-related mortality were analyzed.
Results Of 91,708 eligible patients with MASLD and cirrhosis, PSM yielded 2,107 patients who underwent bariatric surgery and 8,428 non-bariatric controls. Compared to matched controls, patients who underwent bariatric surgery had lower 5-year overall (24.9% vs. 37.1%; p<0.0001), liver-related (3.3% vs. 14%; p<0.0001), and non-liver-related mortality (22.3% vs. 26.9%; p=0.046). In multivariable analysis, bariatric surgery was associated with decreased overall mortality (adjusted hazard ratio [aHR]=0.63; p<0.0001), liver-related (aHR=0.24; p<0.0001), and non-liverrelated (aHR=0.81; p=0.0026) mortality. However, only laparoscopic surgeries were associated with lower overall mortality (aHR=0.39; p<0.0001) whereas open surgeries were associated with higher overall mortality (aHR=1.24; p=0.022).
Conclusions Patients with MASLD and cirrhosis who underwent bariatric surgery, specifically laparoscopic approaches, had significantly lower mortality risk than non-surgical counterparts.
Citations
Citations to this article as recorded by
Arginase 1 promotes hepatic lipogenesis by regulating ERK2/PPARγ signaling in a non-canonical manner Mingyang Shao, Xiaoyue Cao, Yuwei Chen, Ziqi Zhu, Yuke Shu, Qing Tao, Qing Xu, Tingting Ma, Zhenru Wu, Menglin Chen, Yongjie Zhou, Rong Yao, Junhua Gong, Jiayin Yang, Yujun Shi Nature Communications.2026;[Epub] CrossRef
Ultrasound-derived Fat Fraction for Pre-operative Prediction and Monitoring of Hepatic Steatosis Normalization After Metabolic Surgery in Patients With Obesity Die Hu, HuaWu Yang, GeMei Yu, Li Wei, Ying Liu, Hong Zhou, WeiWen Cai, Hong Wen, Guo Li, Shuang Wu, Yang Zhou Ultrasound in Medicine & Biology.2026; 52(6): 1062. CrossRef
Research Progress on the Recompensation of Liver Cirrhosis 源 高 Advances in Clinical Medicine.2026; 16(03): 2709. CrossRef
Metabolic and Bariatric Surgery: The Contraindications of the Past are the Indications of the Future Tala Abedalqader, Joseph Klim, Tony Boutros, Nour El Ghazal, Juan Ignacio Isaac, Andrew G. Robertson, Mohammad Kermansaravi, Omar M. Ghanem Current Obesity Reports.2026;[Epub] CrossRef
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic live Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): 610. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Wei Wang, Yating Xie, Ailei Xu Clinical and Molecular Hepatology.2025; 31(2): e143. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou Clinical and Molecular Hepatology.2025; 31(3): e252. CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018 Yanshan Yi, Li Yang Frontiers in Nutrition.2025;[Epub] CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai Clinical and Molecular Hepatology.2025; 31(3): e247. CrossRef
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis Pandora Fonseca, Leonardo Pereira, João Gabriel Braga, Giovanna Macanhã Scremin, Luísa de Araujo, Julia Alves, Gabriel de França, Pedro Bregion, Rafael Rego, Maria Farias, Victor Ivano Obesity Surgery.2025; 35(10): 4246. CrossRef
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review Janna Vanessa Diaz Torres, Vanessa Rocío Villanueva Guerrero, Jennifer Patricia Vargas Gómez, Fredy Javier Pacheco Miranda, Lorena Rocío Orozco Álvarez, Joseph David León Insignares, Marian Mares, Héctor Mario Rodríguez Ortiz, Evelyn Mendoza-Torres Metabolic Syndrome and Related Disorders.2025; 23(10): 427. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Background/Aims Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the changes in MRI-determined hepatic proton density fat fraction (MRI-PDFF) and nonalcoholic fatty liver disease activity score (NAS) after bariatric surgery or intragastric balloon/gastric banding in MASLD patients with obesity.
Methods We searched various databases including PubMed, OVID Medline, EMBASE, and Cochrane Library. Primary outcomes were the changes in intrahepatic fat on MRI-PDFF and histologic features of metabolic dysfunction-associated steatohepatitis (MASH).
Results Thirty studies with a total of 3,134 patients were selected for meta-analysis. Bariatric intervention significantly reduced BMI (ratio of means, 0.79) and showed 72% reduction of intrahepatic fat on MRI-PDFF at 6 months after bariatric intervention (ratio of means, 0.28). Eight studies revealed that NAS was reduced by 60% at 3–6 months compared to baseline, 40% at 12–24 months, and 50% at 36–60 months. Nineteen studies revealed that the proportion of patients with steatosis decreased by 44% at 3–6 months, 37% at 12–24 months, and 29% at 36–60 months; lobular inflammation by 36% at 12–24 months and 51% at 36–60 months; ballooning degeneration by 38% at 12–24 months; significant fibrosis (≥F2) by 18% at 12–24 months and by 17% at 36–60 months after intervention.
Conclusions Bariatric intervention significantly improved MRI-PDFF and histologic features of MASH in patients with obesity. Bariatric intervention might be the effective alternative treatment option for patients with MASLD who do not respond to lifestyle modification or medical treatment.
Citations
Citations to this article as recorded by
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili Hormones.2026; 25(1): 61. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2026; 335(2): 163. CrossRef
National trend and impact of compensated cirrhosis in patients who underwent metabolic and bariatric surgery: a Nationwide Readmissions Database study Ali Esparham, Stephen Phillippe, Zhamak Khorgami Surgical Endoscopy.2026; 40(3): 2559. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Rhinorrhea and Hiccups After Bariatric Surgery: Exploring Associations with Psychological and Behavioral Factors Marcello Agosta, Maria Sofia, Simona Santonocito, Sara D’Amato, Chiara Mazzone, Cristina Agata Ranno, Salvatore Camiolo, Gaetano La Greca, Saverio Latteri Obesities.2026; 6(1): 13. CrossRef
Ultrasound-derived Fat Fraction for Pre-operative Prediction and Monitoring of Hepatic Steatosis Normalization After Metabolic Surgery in Patients With Obesity Die Hu, HuaWu Yang, GeMei Yu, Li Wei, Ying Liu, Hong Zhou, WeiWen Cai, Hong Wen, Guo Li, Shuang Wu, Yang Zhou Ultrasound in Medicine & Biology.2026; 52(6): 1062. CrossRef
Impact of pathologically diagnosed metabolic dysfunction-associated steatohepatitis on weight loss outcomes following sleeve gastrectomy Yunmiao Pan, Yunfei Qu, Hanchen Ma, Maoge Wang, Mingwei Zhong, Sanyuan Hu Frontiers in Medicine.2026;[Epub] CrossRef
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial Sebastian M. Meyhöfer, Bertrand Cariou, Cintia Cercato, Helen M. Colhoun, John Deanfield, Michelle T. Long, Ole Kleist Jeppesen, A. Michael Lincoff, Ildiko Lingvay, Jorge Plutzky, Philip N. Newsome, Stephen J. Nicholls, Maria Quiroga, Ferruccio Santini, A Nature Medicine.2026;[Epub] CrossRef
Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
The impact of bariatric and metabolic surgery on the levels of circulating growth differentiation factor 15 in humans Victor Yassuda, Beatriz Sequeira, Ana Luísa De Sousa-Coelho Journal of Physiology and Biochemistry.2026;[Epub] CrossRef
Kv1.3 regulates macrophage immune function through PI3K/AKT signaling pathway to alleviate metabolic dysfunction-associated steatohepatitis Ting Ke, Wen-Jun Zhen, Xi-xi Chen, Hao Wang, Shi Chen, Yuan-yuan Tian, Ye-tao Wang, Lei Zhang, Bao-ming Wu Journal of Molecular Medicine.2026;[Epub] CrossRef
Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai Surgery for Obesity and Related Diseases.2025; 21(5): 537. CrossRef
Bariatric nutrition and evaluation of the metabolic surgical patient: Update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS) Sue Benson-Davies, Kirsten Frederiksen, Rutuja Patel Obesity Pillars.2025; 13: 100154. CrossRef
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Xiao-Song Li, Xi-Ping Shen, Hang Li Clinical and Molecular Hepatology.2025; 31(1): e15. CrossRef
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Yuri Cho, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e103. CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot Eda Kaya, Wing-Kin Syn, Paul Manka Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
Perioperative Screening for Metabolic Dysfunction Associated Steatotic Liver Disease in People Undergoing Bariatric Surgery: A Pilot Study David M. Williams, Thinzar Min, Andrew Beamish, Jeffrey W. Stephens Obesity Surgery.2025; 35(5): 1963. CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
Cambios biométricos y metabólicos a un año de seguimiento en pacientes con obesidad e hígado graso sometidos a gastroplastia endoscópica en manga-EndoSleeve (método Apollo) Diego Schwarzstein, Lissette Batista, Patricia Gonçalves, Luis Yip, Leoniana Bustillos, Mar Bacardit, Josep Merlo Revista de la Sociedad Española de Cirugía de Obesidad y Metabólica y de la Sociedad Española para el Estudio de la Obesidad.2025;[Epub] CrossRef
Liver and obesity: a narrative review Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2025; 19(5): 1087. CrossRef
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD) Neha Gupta, Kavita Singh Journal of Molecular Histology.2025;[Epub] CrossRef
Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease Cornelius J Fernandez, Sweekruti Jena, Vijaya Lakshmi, Joseph M Pappachan World Journal of Gastroenterology.2025;[Epub] CrossRef
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo Radiology.2025;[Epub] CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Jing Liu, Yueqiu Wang, Xinghang Zhou, Zaixin Wen, Yu Chen, Yiqiong Sun, Shuaiying Su, Weiwei Lin, Ruiting Shen, Xiaoyu Sun, Hongru Li, Xia Yu, Mingchen Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome Richard H. Goodheart, Oyekoya T. Ayonrinde Heart, Lung and Circulation.2025; 34(10): 1050. CrossRef
Prospective evaluation of a structured group education programme for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Thomas Crame, Rachel Howarth, Elizabeth Johnstone, Hollie Smith, Stuart McPherson, Kate Hallsworth Frontline Gastroenterology.2025; : flgastro-2025-103280. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
The prevalence of obesity and metabolic consequences such as nonalcoholic fatty liver diseases (NAFLD) has become a crucial health problem. Lifestyle modifications, especially weight loss, effectively reduces liver injury in NAFLD patients. However, adherence to lifestyle changes is very low in the clinical setting. Bariatric surgery can improve metabolic components and cause long-term weight loss. Therefore, bariatric surgery could serve as an attractive treatment option for NAFLD patients. This review integrates data about the benefits of bariatric surgery on NAFLD but also describes the potential pitfalls.
Citations
Citations to this article as recorded by
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2026; 32(2): 104. CrossRef
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States Brian P. Lam, Jessica Bartholomew, Sherona Bau, HoChong Gilles, Andrea Keller, Ann Moore, Khalil Nader, Lisa Richards, Linda Henry, Zobair M. Younossi Journal of Clinical Gastroenterology.2025; 59(4): 298. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, Amerta Ghosh, Seema Gulati, Narendra Singh Choudhary, Deep Dutta, Praveen Sharma, Naval K. Vikram, Ashu Rastogi, Akash Shukla, Alpesh Goyal, Amit Gupta, Anand V. Kulkarni, Anil Chandra Anand, Anil Arora, A Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2025; 19(3): 103209. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Post-Metabolic Bariatric Surgery Cirrhosis and the Role of Liver Transplantation: A Report from a Referral Transplant Center Hamed Nikoupour, Erfan Sheikhbahaei, Alireza Shamsaeefar, Kourosh Kazemi, Mohammad Eslamian, Hamidreza Zefreh, Seyed Ali Malek-Hosseini, Saman Nikeghbalian Obesity Surgery.2025; 35(6): 2111. CrossRef
Comparative Analysis of the Incidence of Post-bariatric Cholelithiasis in Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Fernando de Barros, Enmanuel Compres Guichardo, Ana Beatriz Monteiro Fonseca, Leonardo Halamy Pereira, Daniel Alejandro Reyes Encalada Obesity Surgery.2025; 35(8): 3157. CrossRef
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid Cureus.2025;[Epub] CrossRef
Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle Shanshan Liu, Yu Ji, Luyang Wei, Yiqiao Zhang, Linghang Zeng, Yiyang Min, Danyang Yin, Kun Liu, Chengjian Guan, Shumeng Liu, Huajing Yu, Zhongtao Zhang Nature Communications.2025;[Epub] CrossRef
Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes Aryan Shah, Amirhossein Mohammadi, Adeel Haq, David Walji, Boris Zevin Obesity Surgery.2025; 35(10): 4508. CrossRef
Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min Journal of Clinical Medicine.2025; 14(20): 7284. CrossRef
Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD Yujia Shi Hepatology International.2025;[Epub] CrossRef
Development and validation of a noninvasive score for at-risk metabolic dysfunction–associated steatohepatitis in individuals with obesity undergoing bariatric surgery Xin Huang, Tao Zhu, Shumin Li, Teng Liu, Shibo Lin, Hui Liang, Mingwei Zhong, Xitai Sun, Liyong Chen, Hao Bai, Zehua Zhao, Shujuan Lin, Xuehui Chu, Zhiyong Dong, Guangyong Zhang, Shaozhuang Liu Hepatology.2025;[Epub] CrossRef
The hidden burden: incidentalomas detected on abdominopelvic computed tomography in bariatric surgery candidates – a single-center experience Mihaela Toader, Costin Chirica, Liliana Gheorghe, Sabina-Ioana Chirica, Danisia Haba, Ana-Maria Buburuz, Mădălina Maxim, Daniel Vasile Timofte Journal of Medicine and Life.2025; 18(11): 1048. CrossRef
Mid-term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-invasive Diagnosis Èlia Navarro-Masip, Núria Mestres, Marta Zorzano-Martínez, Blanca Salinas-Roca, Enric Sánchez, Carolina López-Cano, Fernando Herrerías, Mari Cruz de la Fuente, Maite Santamaría, Josep León-Mengíbar, Ana-Gloria Soler, Marta Bueno, Albert Lecube Obesity Surgery.2024; 34(3): 841. CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Bacteroides and NAFLD: pathophysiology and therapy Jun Zhang, Jing Zhou, Zheyun He, Hongshan Li Frontiers in Microbiology.2024;[Epub] CrossRef
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman Alimentary Pharmacology & Therapeutics.2024; 60(2): 167. CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
The Role of Preoperative Abdominal Ultrasound in the Preparation of Patients Undergoing Primary Metabolic and Bariatric Surgery: A Machine Learning Algorithm on 4418 Patients’ Records Mohamed Hany, Mohamed El Shafei, Mohamed Ibrahim, Ann Samy Shafiq Agayby, Anwar Ashraf Abouelnasr, Moustafa R. Aboelsoud, Ehab Elmongui, Bart Torensma Obesity Surgery.2024; 34(9): 3445. CrossRef
Cytokeratin 18 in nonalcoholic fatty liver disease: value and application Yuan Wu, Jing Zhou, Jun Zhang, Hongshan Li Expert Review of Molecular Diagnostics.2024; 24(11): 1009. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients Álvaro Pérez-Rubio, Polina Soluyanova, Erika Moro, Guillermo Quintás, Iván Rienda, María Dolores Periañez, Andrés Painel, José Vizuete, Judith Pérez-Rojas, José V. Castell, Ramón Trullenque-Juan, Eugenia Pareja, Ramiro Jover Nutrients.2023; 15(14): 3187. CrossRef
First
Prev
